OneSpan Inc (NASDAQ: OSPN) has reported a loss for its third fiscal quarter (ending September 30) of $-0.10 versus a loss $-0.18 for the same period a year ago. Relative to the consensus estimate of […]
Theravance Biopharma Inc (NASDAQ: TBPH). Extremely significant positive changes in investment behavior have recently occurred: its shorter term price trend turned up, the stock’s recent price rise disrupted its longer term downtrend, positive upside/downside volume […]
Travere Therapeutics Inc (NASDAQ: TVTX) stock suffered a major decline of -11.8% on 11/8/23. The shares closed at $6.33. The stock has been extremely weak relative to the market over the last nine months and […]
VistaGen Therapeutics Inc (NASDAQ: VTGN) stock closed at $3.08 on 11/8/23 after a major decline of -11.4%. Relative to the market the stock has been weak over the last nine months and has declined -3.1% […]
Envestnet Inc (NYSE: ENV) has reported E.P.S. of $0.13 for its third fiscal quarter (ending September 30) versus $-0.13 for the same period a year ago. Relative to the consensus estimate of $0.54, this was […]
Amicus Therapeutics Inc (NASDAQ: FOLD) has reported E.P.S. of $-0.07 for its third fiscal quarter (ending September 30) versus $-0.12 for the same period a year ago. Relative to the consensus estimate of $-0.08, this […]
Topgolf Callaway Brands Corp (NYSE: MODG) has reported E.P.S. of $0.16 for its third fiscal quarter (ending September 30) versus $0.21 for the same period a year ago — a decline of -24%. However, this […]
3D Systems Corp (NYSE: DDD) has reported E.P.S. of $-0.09 for its third fiscal quarter (ending September 30) versus $-0.30 for the same period a year ago. Relative to the consensus estimate of $-0.07, this […]
Ashland Inc (NYSE: ASH) has reported E.P.S. of $-0.15 for its fourth fiscal quarter (ending September 30) versus $1.13 for the same period a year ago — a decline of -113%. Relative to the consensus […]
For its third fiscal quarter (ending September 30), Ligand Pharmaceuticals Inc (NASDAQ: LGND) has reported a -154% decline in E.P.S. from $1.37 a year ago to $-0.74 in the current quarter. This performance was $-1.36 […]
Privacy Statement Terms Of Use ©2024 PriceTarget Research